Fore score

How Cerecor's forebrain-specific GRIA antagonist sidelines GRIA's side effects

Cerecor Inc. (NASDAQ:CERC) has picked up a forebrain-selective anti-epileptic compound from Eli Lilly and Co. (NYSE:LLY) that could treat seizures by blocking AMPA glutamate receptor (GRIA; GLUR) without the dose-limiting motor side effects associated with that target.

Cerecor added CERC-611 - formerly LY3130418 - to its arsenal of neurological programs in an October deal with Lilly. Last month in Nature Medicine, Lilly researchers reported the compound

Read the full 659 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE